A 76-year-old patient with chronic, pretreated, active neovascular age related macular degeneration is receiving ongoing anti-VEGF injections. They ask whether one-off stereotactic radiotherapy is supported by longer-term trial evidence.
Based on the STAR abstract, what does the year 4 evidence support?